Home > Insider Trading > Filing (0001567619-19-015484)

Filing Details

Accession Number:: 0001567619-19-015484
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-30 19:37:00
Reporting Period:: 2019-07-26

Accepted Time:: 2019-07-30 19:37:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1348911	Kalvista Pharmaceuticals Inc.	KALV	Pharmaceutical Preparations (2834)	200915291

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1397906	Albert Cha	C/O Kalvista Pharmaceuticals, Inc. 55 Cambridge Parkway, Suite 901E Cambridge MA 02142		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-26	4,558	$16.83	119,429	No	4	P	Indirect	By Vivo Capital Fund IX, L.P.
Common Stock	Acquisiton	2019-07-26	21,942	$16.83	997,763	No	4	P	Indirect	By Vivo Opportunity Fund, L.P.
Common Stock	Acquisiton	2019-07-29	24,730	$17.13	1,022,493	No	4	P	Indirect	By Vivo Opportunity Fund, L.P.
Common Stock	Acquisiton	2019-07-29	5,137	$17.13	124,566	No	4	P	Indirect	By Vivo Capital Fund IX, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Vivo Capital Fund IX, L.P.
No	4	P	Indirect	By Vivo Opportunity Fund, L.P.
No	4	P	Indirect	By Vivo Opportunity Fund, L.P.
No	4	P	Indirect	By Vivo Capital Fund IX, L.P.

Footnotes

The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.47 to $16.85 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Albert Cha, Shan Fu, Edgar Engleman and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares.
The shares are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares.
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.94 to $17.83 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.